TLX Stock Analysis: Buy, Sell, or Hold?
TLX - Telix Pharmaceuticals Limited American Depositary Shares
$10.44
0.04 (0.38%)
▲
5d:
+2.05%
30d:
+13.48%
90d:
+24.88%
BUY
MODERATE Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 21, 2026
21d
Get Alerted When TLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TLX shows positive signals but monitor for confirmation. Market pricing in 9.3% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: TLX shows positive signals but monitor for confirmation. Market pricing in 9.3% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.56
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$9.66
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 23.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TLX is currently trading at $10.44, which is considered slightly high relative to its 30-day fair value range of $9.18 to $10.64. From a valuation perspective, the stock is trading at a premium (Forward PE: 30.3) compared to its historical average (23.2). At these levels, the market is pricing in 9.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TLX is in a strong downtrend. Immediate support is located at $10.06, while resistance sits at $11.25.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.67 (+107.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TLX is in a strong downtrend. Immediate support is located at $10.06, while resistance sits at $11.25.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.67 (+107.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$9.18 -
$10.64
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
64.3%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 107.6% below Wall St target ($21.67)
- NEUTRAL: Trading at premium valuation - market expects 9.3% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$9.18 -
$10.64
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$10.06
Resistance Level
$11.25
Current Trend
Strong Downtrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
30.30
Wall Street Target
$21.67
(+107.6%)
Revenue Growth (YoY)
49.3%
Profit Margin
-0.9%
Valuation Premium vs History
+9.3% premium
PE vs Historical
30.3 vs 23.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+9.3%
(market-implied from PE analysis)
1-Year Target
$11.41
(+9%)
2-Year Target
$12.47
(+20%)
3-Year Target
$13.63
(+31%)
3-Yr Target (if PE normalizes)
(PE: 30→23)
PE COMPRESSION
$10.44
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 30.3, Growth: 224.7%)
$35.23
(+238%)
Base:
(SPY PE: 20.6, Growth: 224.7%)
$23.96
(+130%)
Bear:
(PE: 17.5, Growth: 224.7%)
$20.37
(+95%)
Share & Embed Analysis
Last updated: April 29, 2026 9:43 AM ET
Data refreshes hourly during market hours. Next update: 10:43 AM
Data refreshes hourly during market hours. Next update: 10:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TLX showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 52 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 60 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 57 HOLD |
